GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

AptaBio Therapeutics 293780.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

4,730

-3.47%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About AptaBio Therapeutics

Its shares trade on KOSDAQ under the ticker 293780.KQ. It has been listed since 12 June 2019. In the fiscal year to 31 December 2025, it reported revenue of ₩3.70bn and a net loss of ₩16.35bn. At that date it held total assets of ₩60.03bn and shareholders' equity of ₩47.18bn.

Aptabio Therapeutics, Inc. operates as a pharmaceutical biotechnology company that develops intractable innovative drugs based on original platform technology. The company is headquartered in Yongin, Gyeonggi-Do. The company went IPO on 2019-06-12. The firm is developing anti-cancer drugs, drugs for inflammatory and fibrotic diseases and diabetic complications drugs, among others.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
12 Jun 2019
Employees
26
Website
aptabio.com ↗

Leadership

Pay as last reported

  • Mr. Seong Hwan MoonPresident, Chief Technology Officer, Director
  • Ms. Su Jin LeeChief Executive Officer, Director
  • Mr. Jun Hui JungChief Financial Officer
  • Mr. Jeong Ho ParkInternal Auditor
  • Mr. Yeong Gwang OhOther Non-Executive Director
  • Mr. Sun Gwang HongNon-Executive Independent Director
  • Mr. Jong Nam SeoNon-Executive Independent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • AptaBio Therapeutics Inc. develops innovative anti-cancer drugs using original platform technology.
  • The company focuses on intractable diseases with drugs for inflammatory and fibrotic conditions.
  • AptaBio Therapeutics Inc. has 26 employees and operates in the Health Care sector.

Weaknesses

  • AptaBio Therapeutics Inc. is a small company with only 26 employees.
  • The company's IPO was on 12 June 2019, indicating limited market history.
  • AptaBio Therapeutics Inc. operates in a highly competitive biotechnology sector.

Opportunities

  • AptaBio Therapeutics Inc. targets the growing market for anti-cancer drugs in South Korea.
  • The company can expand its drug portfolio for diabetic complications in the Health Care sector.
  • AptaBio Therapeutics Inc. may benefit from increased investment in biotechnology in KR.

Threats

  • AptaBio Therapeutics Inc. faces competition from established biotechnology firms in KR.
  • The company's small size may limit its ability to compete with larger pharmaceutical companies.
  • Regulatory challenges in the Health Care sector could impact drug development timelines.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.